
Uremic toxins may offer therapeutic targets to improve muscle health in PAD patients with CKD. The study of 123 participants (28 controls, 46 PAD-only, 31 CKD-only, 18 PAD + CKD) shows how CKD exacerbates PAD, reducing muscle strength by 40%, impairing mitochondrial function, and altering gene expression. Using multiomics, significant correlations between uremic toxins and muscle dysfunction were found. Targeting these changes could improve patient outcomes.
Like
Save
Share